Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at 2026 AACR Annual Conference

Biopharmaceutical company to showcase tumor-activated oncology delivery platform at leading cancer research event

Mar. 17, 2026 at 7:33am

Got story updates? Submit your updates here. ›

Avacta Therapeutics, a clinical-stage biopharmaceutical company, announced it will deliver two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California. The presentations will focus on the company's pre|CISION® tumor-activated oncology delivery platform and its pipeline of peptide drug conjugates (PDCs) and Affimer® drug conjugates (AffDCs).

Why it matters

Avacta's pre|CISION® platform is designed to concentrate highly potent cancer payloads in the tumor microenvironment while sparing normal tissues, potentially improving the therapeutic index of these treatments. The presentations at AACR will showcase the preclinical and translational development of this innovative approach to delivering cancer therapies.

The details

The first presentation, titled "AVA6103 is a FAP-enabled pre|CISION® peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activity", will highlight a PDC that leverages the tumor-specific protease fibroblast activation protein (FAP) to release the payload in the tumor. The second presentation, "Characterization and translational development of novel pre|CISION® technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage", will focus on pre|CISION® compounds that can deliver two complementary payloads to the tumor.

  • The AACR Annual Meeting 2026 will take place from April 17, 2026 to April 22, 2026 in San Diego, California.
  • Avacta's two presentations are scheduled for Tuesday, April 21, 2026 from 2:00-5:00pm PDT.

The players

Avacta Therapeutics

A clinical-stage biopharmaceutical company developing the pre|CISION® tumor-activated oncology delivery platform.

American Association for Cancer Research (AACR)

A leading organization for cancer research that hosts the annual AACR Annual Meeting, a major event for the cancer research community.

Got photos? Submit your photos here. ›

The takeaway

Avacta's presentations at the AACR Annual Meeting highlight the potential of its pre|CISION® platform to improve the delivery and efficacy of cancer therapies by concentrating potent payloads in the tumor microenvironment. This innovative approach could lead to more effective and safer treatments for cancer patients.